Can Gynecological Cancers Be Effectively Prevented in Women with Lynch Syndrome?
Lynch syndrome is a hereditary condition that significantly increases the risk of developing several types of cancer, particularly uterine and ovarian cancers. Affected women have an increased risk of endometrial cancer, which can reach up to 46% before the age of 75 depending on the gene involved, and an ovarian cancer risk of up to 13%. These figures highlight the importance of finding appropriate prevention strategies.
Preventive surgery, such as the removal of the uterus and ovaries, remains the most effective method for reducing these risks. However, this procedure leads to early menopause and can impact quality of life. It is not always chosen by women, especially those who wish to preserve their fertility or avoid the side effects associated with artificial menopause.
Regular gynecological monitoring, based on ultrasounds and endometrial biopsies, is often proposed as an alternative. Yet, studies show that this approach does not significantly reduce mortality related to these cancers. Current screening techniques lack sensitivity, especially in younger women, and may miss precancerous lesions or early-stage cancers. Additionally, protocols vary by country and center, making it difficult to assess their true effectiveness.
Recent advances are opening new avenues. DNA analysis in vaginal or cervical samples could enable early and non-invasive detection of cancers. Biological markers, such as the methylation of certain genes, are being studied to improve diagnostic accuracy. Preventive vaccines targeting the specific genetic abnormalities of Lynch syndrome are also under development, but their efficacy has yet to be confirmed.
Aspirin and certain hormonal treatments, such as oral contraceptives or hormone-releasing IUDs, may reduce the risk of endometrial cancer. However, their use in this specific context requires further research to be validated.
Finally, while a healthy lifestyle is recommended for overall health, its direct impact on preventing gynecological cancers in women with Lynch syndrome remains uncertain. Therapeutic choices should therefore be personalized, taking into account each patient’s wishes, age, and family history.
Future research will need to focus on clinical trials to validate these new approaches, assess their acceptability, and evaluate their cost-effectiveness. The goal is to offer less invasive and more tailored solutions while improving the overall management of these high-risk patients.
Sources
About This Study
DOI: https://doi.org/10.1007/s10689-026-00548-1
Title: Prevention strategies for hereditary gynaecological cancer in Lynch syndrome
Journal: Familial Cancer
Publisher: Springer Science and Business Media LLC
Authors: Kevin J. J. Kwinten; Jean-Ellen Johnson; Anne M. van Altena; Nicoline Hoogerbrugge; Emma J. Davidson; Joanne A. de Hullu